{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:18:12Z","timestamp":1784546292724,"version":"3.55.0"},"reference-count":228,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008842","name":"Nanjing Xiaozhuang University","doi-asserted-by":"publisher","award":["4172135"],"award-info":[{"award-number":["4172135"]}],"id":[{"id":"10.13039\/501100008842","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22207055"],"award-info":[{"award-number":["22207055"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21801127"],"award-info":[{"award-number":["21801127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22408180"],"award-info":[{"award-number":["22408180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bcp.2026.117802","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:34:27Z","timestamp":1770856467000},"page":"117802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dual-targeting Bcl-2-mediated apoptosis and synergistic pathways: Combinatorial strategies to overcome therapeutic resistance in cancer"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-3880","authenticated-orcid":false,"given":"Jiongjia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0015","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis."},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0020","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat. Rev. Clin.Oncol."},{"key":"10.1016\/j.bcp.2026.117802_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113064","article-title":"The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine","volume":"150","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.117802_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122907","article-title":"Drug resistance in human cancers - Mechanisms and implications","volume":"352","author":"Vijayakumar","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.117802_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102973","article-title":"Medical management of pancreatic cancer: from personalization to broadening treatment strategies","volume":"138","author":"Dusetti","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.117802_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: New insights and future directions","volume":"229","author":"Espona-Fiedler","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","article-title":"Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance","volume":"10","author":"Song","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117802_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108388","article-title":"Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy","volume":"159","author":"Chaudhary","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0070","doi-asserted-by":"crossref","first-page":"180002","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.117802_b0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bcp.2019.01.015","article-title":"A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics","volume":"162","author":"Knight","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","article-title":"Targeting BCL-2-like Proteins to Kill Cancer Cells","volume":"2","author":"Cory","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2026.117802_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114184","article-title":"Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment","volume":"232","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.21707","article-title":"Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities","volume":"104","author":"Plati","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b0115","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/cdd.2011.17","article-title":"The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy","volume":"18","author":"Kelly","year":"2011","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nchembio.391","article-title":"The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer","volume":"6","author":"Stewart","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.117802_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.864874","article-title":"Structural Details of BH3 Motifs and BH3-Mediated Interactions: an Updated Perspective","volume":"9","author":"Sora","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bbamcr.2010.11.024","article-title":"BH3-only proteins: Orchestrators of apoptosis","volume":"1813","author":"Shamas-Din","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.117802_b0135","first-page":"S2","article-title":"BH3-only proteins in apoptosis and beyond: an overview","volume":"1","author":"Lomonosova","year":"2008","journal-title":"Oncogene 27 Suppl"},{"issue":"6009","key":"10.1016\/j.bcp.2026.117802_b0140","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.1190217","article-title":"and PUMA are essential for activation of the BAX- and BAK-dependent cell death program","volume":"330","author":"Ren","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov."},{"issue":"45","key":"10.1016\/j.bcp.2026.117802_b0150","doi-asserted-by":"crossref","first-page":"27980","DOI":"10.1073\/pnas.2008885117","article-title":"Mcl-1 and Bok transmembrane domains: Unexpected players in the modulation of apoptosis","volume":"117","author":"Lucendo","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"48","key":"10.1016\/j.bcp.2026.117802_b0155","doi-asserted-by":"crossref","first-page":"25207","DOI":"10.1074\/jbc.M116.733634","article-title":"The C-terminal Domains of Apoptotic BH3-only Proteins Mediate Their Insertion into Distinct Biological Membranes","volume":"291","author":"Andreu-Fern\u00e1ndez","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b0160","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1038\/s44319-024-00206-6","article-title":"BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains","volume":"25","author":"Beigl","year":"2024","journal-title":"EMBO Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1073\/pnas.1612322114","article-title":"Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes","volume":"114","author":"Andreu-Fern\u00e1ndez","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/biom10010128","article-title":"The Bcl-2 Family: Ancient Origins, Conserved Structures, and Divergent Mechanisms","volume":"10","author":"Banjara","year":"2020","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b0175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2017.179","article-title":"MOMP, cell suicide as a BCL-2 family business","volume":"25","author":"Kalkavan","year":"2018","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0185","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/ncb1499","article-title":"Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies","volume":"8","author":"Kim","year":"2006","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0190","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","article-title":"Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol","volume":"145","author":"Edlich","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/cdd.2013.139","article-title":"Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis","volume":"21","author":"Westphal","year":"2014","journal-title":"Cell Death Differ."},{"issue":"5517","key":"10.1016\/j.bcp.2026.117802_b0200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0205","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Del Gaizo Moore","year":"2013","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.bcp.2026.117802_b0210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.tibs.2025.09.001","article-title":"Mitochondrial dynamics and pore formation in regulated cell death pathways","volume":"50","author":"Hohorst","year":"2025","journal-title":"Trends Biochem. Sci"},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183716","article-title":"Apoptosis regulation at the mitochondria membrane level","volume":"1863","author":"Dadsena","year":"2021","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0220","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1101\/gad.276725.115","article-title":"Inactivation of prosurvival Bcl-2 proteins activates Bax\/Bak through the outer mitochondrial membrane","volume":"30","author":"O'Neill","year":"2016","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0225","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41580-022-00564-w","article-title":"Pore-forming proteins as drivers of membrane permeabilization in cell death pathways","volume":"24","author":"Vandenabeele","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0230","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cell.2012.12.031","article-title":"Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis","volume":"152","author":"Czabotar","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0235","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.18632\/oncotarget.6405","article-title":"Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species","volume":"7","author":"Um","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0240","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/cr.2010.149","article-title":"Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX","volume":"21","author":"Ku","year":"2011","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13046-021-02157-5","article-title":"BH3-mimetics: recent developments in cancer therapy","volume":"40","author":"Townsend","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.bcp.2026.117802_b0250","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.2174\/1568026619666190119144819","article-title":"Homology Modeling and Docking Studies of Bcl-2 and Bcl-xL with Small Molecule Inhibitors: Identification and Functional Studies","volume":"18","author":"Salam","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0255","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41418-017-0010-6","article-title":"Mcl-1 and Bcl-x(L) sequestration of Bak confers differential resistance to BH3-only proteins","volume":"25","author":"Hockings","year":"2018","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b0260","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1535-7163.MCT-13-0058","article-title":"BH3 mimetics: status of the field and new developments","volume":"12","author":"Billard","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0270","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"7042","key":"10.1016\/j.bcp.2026.117802_b0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b0280","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 pathway inhibition in solid tumors: a review of clinical trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0285","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bcp.2026.117802_b0290","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fcell.2020.00354","article-title":"The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice","volume":"8","author":"Sharma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.117802_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100889","article-title":"Precision medicine: Ray of hope in overcoming cancer multidrug resistance","volume":"65","author":"Musyuni","year":"2022","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2026.117802_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.bcp.2026.117802_b0305","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4155\/fmc-2018-0366","article-title":"Targeting cancer's Achilles' heel: role of BCL-2 inhibitors in cellular senescence and apoptosis","volume":"11","author":"Anantram","year":"2019","journal-title":"Future Med. Chem."},{"issue":"28","key":"10.1016\/j.bcp.2026.117802_b0310","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.18632\/oncotarget.24744","article-title":"S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth","volume":"9","author":"Casara","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.117802_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101510","article-title":"Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities","volume":"26","author":"Fu","year":"2022","journal-title":"Transl. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0320","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/1535-7163.MCT-24-1096","article-title":"BCL-2 family inhibition enhances MTORC1\/2 inhibition in PIK3CA mutant colorectal cancer","volume":"24","author":"DeStefanis","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b0325","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0330","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41419-017-0044-1","article-title":"Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition","volume":"9","author":"Serasinghe","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.117802_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1398419","article-title":"Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road","volume":"15","author":"R\u00edos-Hoyo","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0340","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bcp.2026.117802_b0345","doi-asserted-by":"crossref","unstructured":"X. Ou, G. Gao, I.A. Habaz, Y. Wang, Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies, MedComm (2020) 5(9) (2024) e694.","DOI":"10.1002\/mco2.694"},{"key":"10.1016\/j.bcp.2026.117802_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100798","article-title":"Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2\/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis","volume":"29","author":"Yao","year":"2022","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b0355","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","article-title":"Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia","volume":"13","author":"Glytsou","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b0360","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.bcp.2026.117802_b0365","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x(L), Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0370","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bcp.2026.117802_b0375","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1182\/blood-2023-179168","article-title":"Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I\/II Trial","volume":"142","author":"Arslan","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0380","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2024013423","article-title":"Antileukemia efficacy of the dual BCL2\/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models","volume":"9","author":"Kannan","year":"2025","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0385","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41419-024-06478-z","article-title":"BCL-X(L) inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF(V600E) colorectal cancer","volume":"15","author":"Jenkins","year":"2024","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0390","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0395","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0400","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0405","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)-Specific Degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0410","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.bcp.2026.117802_b0415","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","article-title":"Discovery of a Novel BCL-X(L) PROTAC Degrader with Enhanced BCL-2 Inhibition","volume":"64","author":"Pal","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0420","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0425","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0430","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41467-020-15838-0","article-title":"Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity","volume":"11","author":"He","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117802_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-X(L) degraders as potent anticancer agents with low on-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0440","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117802_b0445","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/bs.ircmb.2020.01.002","article-title":"Mcl-1 as a \u201cbarrier\u201d in cancer treatment: Can we target it now?","volume":"351","author":"Pervushin","year":"2020","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0450","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.bcp.2026.117802_b0455","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0460","first-page":"1582","article-title":"AMG 176, a Selective MCL1 Inhibitor","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies, Cancer Discov."},{"issue":"21","key":"10.1016\/j.bcp.2026.117802_b0465","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221967120","article-title":"Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1","volume":"120","author":"Hargreaves","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2026.117802_b0470","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.taap.2018.09.041","article-title":"Role of Mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro","volume":"360","author":"Guo","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0475","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10549-018-5022-5","article-title":"Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer","volume":"173","author":"Vallet","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0480","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41418-025-01481-z","article-title":"The BCL-2 protein family: from discovery to drug development","volume":"32","author":"Croce","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2026.117802_b0485","doi-asserted-by":"crossref","first-page":"9859","DOI":"10.3390\/ijms26209859","article-title":"Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies","volume":"26","author":"Mukherjee","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b0490","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1038\/cddis.2015.141","article-title":"Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction","volume":"6","author":"Robin","year":"2015","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0495","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.bcp.2026.117802_b0500","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41571-025-01068-0","article-title":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia","volume":"22","author":"Glaviano","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117802_b0505","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.991554","article-title":"Hypericin, a potential new BH3 mimetic","volume":"13","author":"Doroshenko","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117802_b0510","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pdpdt.2019.08.016","article-title":"Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels","volume":"28","author":"Stroffekova","year":"2019","journal-title":"Photodiagnosis Photodyn. Ther."},{"issue":"20","key":"10.1016\/j.bcp.2026.117802_b0515","doi-asserted-by":"crossref","first-page":"e3401","DOI":"10.21769\/BioProtoc.3401","article-title":"Measuring Small-molecule Inhibition of Protein Interactions in Live Cells Using FLIM-FRET","volume":"9","author":"Pemberton","year":"2019","journal-title":"Bio. Protoc."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0520","doi-asserted-by":"crossref","first-page":"10621","DOI":"10.1038\/s41467-025-65509-1","article-title":"Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism","volume":"16","author":"Maillet","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117802_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113038","article-title":"Development of Mcl-1 inhibitors for cancer therapy","volume":"210","author":"Negi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0530","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/acs.jmedchem.3c02206","article-title":"Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen","volume":"67","author":"Hekking","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0535","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41416-023-02219-9","article-title":"Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer","volume":"128","author":"Valko","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0540","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/CAD.0000000000001553","article-title":"Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer","volume":"35","author":"Wang","year":"2024","journal-title":"Anti-Cancer Drug."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0545","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1002\/cam4.3090","article-title":"Bcl-2\/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma","volume":"9","author":"Yi","year":"2020","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0550","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","article-title":"First-in-Human Study with Preclinical Data of BCL-2\/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors","volume":"30","author":"Lakhani","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12672-022-00470-9","article-title":"Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells","volume":"13","author":"Abdul Rahman","year":"2022","journal-title":"Discov. Oncol."},{"issue":"7626","key":"10.1016\/j.bcp.2026.117802_b0560","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117802_b0565","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.041","article-title":"Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X(L) and MCL-1 leads to rapid induction of intrinsic apoptosis","volume":"482","author":"Kehr","year":"2020","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0570","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X(L) Inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b0575","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.3390\/ijms25063453","article-title":"Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2\/Bcl-x(L)\/Bcl-w Inhibitors","volume":"25","author":"Peng","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117802_b0580","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2017.03.006","article-title":"Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects","volume":"136","author":"Opydo-Chanek","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0585","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0595","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11030-022-10494-6","article-title":"Identification of bicyclic compounds that act as dual inhibitors of Bcl-2 and Mcl-1","volume":"27","author":"Uthale","year":"2023","journal-title":"Mol. Divers."},{"issue":"27","key":"10.1016\/j.bcp.2026.117802_b0600","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non-Canonical Amino Acids for Coinhibition of MCL-1 and BCL-xL in Acute Myeloid Leukemia","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (weinh)"},{"key":"10.1016\/j.bcp.2026.117802_b0605","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejmech.2018.01.100","article-title":"Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A","volume":"148","author":"Abou Samra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b0610","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.bmc.2017.02.014","article-title":"Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2\/Mcl-1 dual inhibitors","volume":"25","author":"Liu","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117802_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107687","article-title":"Discovery and development of thiazolidine-2,4-dione derivatives as Bcl-2\/Mcl-1 dual inhibitors","volume":"151","author":"Long","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2026.117802_b0620","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1016\/j.bmc.2017.08.024","article-title":"1-Phenyl-1H-indole derivatives as a new class of Bcl-2\/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation","volume":"25","author":"Xu","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0625","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1039\/D2MD00277A","article-title":"Discovery of N-sulfonylated aminosalicylic acids as dual MCL-1\/BCL-xL inhibitors","volume":"14","author":"Chen","year":"2023","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0630","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0635","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0640","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1039\/D2MD00095D","article-title":"Scaffold hopping from indoles to indazoles yields dual MCL-1\/BCL-2 inhibitors from MCL-1 selective leads","volume":"13","author":"Drennen","year":"2022","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0645","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/ijms15022494","article-title":"Survivin as a preferential target for cancer therapy","volume":"15","author":"Mobahat","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0650","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/med.21547","article-title":"Therapeutic strategies involving survivin inhibition in cancer","volume":"39","author":"Mart\u00ednez-Garc\u00eda","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2026.117802_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122788","article-title":"Survivin (BIRC5): Implications in cancer therapy","volume":"350","author":"Siragusa","year":"2024","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b0660","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18150","article-title":"Targeted inhibition of colorectal cancer proliferation: The dual-modulatory role of 2,4-DTBP on anti-apoptotic Bcl-2 and Survivin proteins","volume":"28","author":"Saha","year":"2024","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0665","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41420-025-02670-y","article-title":"Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions","volume":"11","author":"Qiu","year":"2025","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0670","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tips.2021.11.001","article-title":"Physiological and pharmacological modulation of BAX","volume":"43","author":"Spitz","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0675","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/cdd.2012.9","article-title":"BH3-only proteins are tail-anchored in the outer mitochondrial membrane and can initiate the activation of Bax","volume":"19","author":"Wilfling","year":"2012","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0680","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.celrep.2016.11.064","article-title":"Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance","volume":"17","author":"P\u00e9cot","year":"2016","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b0685","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.apsb.2024.02.010","article-title":"Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"7216","key":"10.1016\/j.bcp.2026.117802_b0690","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nature07396","article-title":"BAX activation is initiated at a novel interaction site","volume":"455","author":"Gavathiotis","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0695","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41589-018-0223-0","article-title":"Small-molecule allosteric inhibitors of BAX","volume":"15","author":"Garner","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0700","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41467-022-28741-7","article-title":"Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer","volume":"13","author":"Lopez","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0705","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111826","article-title":"BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis","volume":"41","author":"Bharti","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0715","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0720","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/s41467-021-22655-6","article-title":"Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.bcp.2026.117802_b0725","doi-asserted-by":"crossref","first-page":"23374","DOI":"10.1021\/acsnano.3c04112","article-title":"Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma","volume":"17","author":"Schnorenberg","year":"2023","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0730","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/med.21637","article-title":"Targeting MDM2 for novel molecular therapy: Beyond oncology","volume":"40","author":"Wang","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0735","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future","volume":"76","author":"Wang","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.117802_b0740","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.biopha.2018.10.155","article-title":"Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment","volume":"109","author":"Gupta","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0745","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"51","key":"10.1016\/j.bcp.2026.117802_b0750","doi-asserted-by":"crossref","first-page":"12159","DOI":"10.1021\/bi901188s","article-title":"The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif","volume":"48","author":"Xu","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.117802_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114637","article-title":"Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors","volume":"241","author":"Espadinha","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0760","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1038\/s41467-023-40087-2","article-title":"Structures of p53\/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity","volume":"14","author":"Wei","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b0765","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0770","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","article-title":"New insights into protein-protein interaction modulators in drug discovery and therapeutic advance","volume":"9","author":"Nada","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117802_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107544","article-title":"Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment","volume":"211","author":"Camps-Fajol","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"30","key":"10.1016\/j.bcp.2026.117802_b0780","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1002\/anie.201802003","article-title":"Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin","volume":"57","author":"Zhu","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"20","key":"10.1016\/j.bcp.2026.117802_b0785","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b0790","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1021\/acs.jmedchem.5b01913","article-title":"Bcl-2\/MDM2 Dual Inhibitors Based on Universal Pyramid-Like \u03b1-Helical Mimetics","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bcp.2026.117802_b0795","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cmdc.202000278","article-title":"Rationally Designed Polypharmacology: \u03b1-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1\u2009and HDM2","volume":"15","author":"Conlon","year":"2020","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0800","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbrc.2019.04.009","article-title":"A novel mechanism of irinotecan targeting MDM2 and Bcl-xL","volume":"514","author":"Lee","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0805","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/cdd.2008.31","article-title":"ABT-737, proving to be a great tool even before it is proven in the clinic","volume":"15","author":"Vaux","year":"2008","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0810","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/cdd.2008.25","article-title":"A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells","volume":"15","author":"Vogler","year":"2008","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189150","article-title":"Histone deacetylase complexes: Structure, regulation and function","volume":"1879","author":"Asmamaw","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b0820","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: Trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104094","article-title":"Targeting histone deacetylases: Emerging applications beyond cancer","volume":"29","author":"Raouf","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"23","key":"10.1016\/j.bcp.2026.117802_b0830","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/MCB.01481-08","article-title":"Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1","volume":"29","author":"Chen","year":"2009","journal-title":"Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0835","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0840","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/2159-8290.CD-12-0417","article-title":"Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma","volume":"3","author":"He","year":"2013","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.bcp.2026.117802_b0845","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-11-0046","article-title":"Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma","volume":"71","author":"Ramsey","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0850","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15384047.2015.1108485","article-title":"Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer","volume":"17","author":"Nakajima","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0855","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41420-025-02632-4","article-title":"Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma","volume":"11","author":"Huang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"11\u201312","key":"10.1016\/j.bcp.2026.117802_b0860","first-page":"445","article-title":"The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells, Genes","volume":"5","author":"Berghauser Pont","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0865","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bmcl.2018.12.052","article-title":"Design, synthesis, and bioactivity evaluation of novel Bcl-2\/HDAC dual-target inhibitors for the treatment of multiple myeloma","volume":"29","author":"Zhou","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0870","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70084","article-title":"Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2\/HDAC1 and Dual BCL-2\/HDAC6 Inhibitors","volume":"86","author":"Chan","year":"2025","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2026.117802_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103012","article-title":"Autophagy as a critical driver of metabolic adaptation, therapeutic resistance, and immune evasion of cancer","volume":"84","author":"Yamamoto","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0880","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/cdd.2017.22","article-title":"Non-apoptotic functions of BCL-2 family proteins","volume":"24","author":"Gross","year":"2017","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.bcp.2026.117802_b0885","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.4161\/auto.29639","article-title":"BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy","volume":"10","author":"Lindqvist","year":"2014","journal-title":"Autophagy"},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b0890","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tcb.2020.03.004","article-title":"Noncanonical Cell Fate Regulation by Bcl-2 Proteins","volume":"30","author":"Chong","year":"2020","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0895","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0900","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0905","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0910","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0704","article-title":"Allosteric PI3K\u03b1 Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0915","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12967-025-06595-z","article-title":"The dual role of autophagy in cancer stem cells: implications for tumor progression and therapy resistance","volume":"23","author":"Jia","year":"2025","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0920","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ncb1192","article-title":"Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes","volume":"6","author":"Shimizu","year":"2004","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0925","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b0930","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117802_b0935","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.117802_b0940","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1007\/s11033-021-06786-z","article-title":"Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines","volume":"48","author":"Avsar Abdik","year":"2021","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b0945","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15548627.2015.1017191","article-title":"BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy","volume":"11","author":"Pedro","year":"2015","journal-title":"Autophagy"},{"issue":"11","key":"10.1016\/j.bcp.2026.117802_b0950","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/pros.23843","article-title":"Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide","volume":"79","author":"Pilling","year":"2019","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0955","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1021\/acs.molpharmaceut.8b00696","article-title":"T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas","volume":"15","author":"Cheng","year":"2018","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b0960","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.7150\/jca.29192","article-title":"Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo","volume":"10","author":"Nayman","year":"2019","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","article-title":"Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice","volume":"9","author":"Khan","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2026.117802_b0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110397","article-title":"Dual PI3K\/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy","volume":"129","author":"Hu","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b0975","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cells3020418","article-title":"Mcl-1 ubiquitination: unique regulation of an essential survival protein","volume":"3","author":"Mojsa","year":"2014","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b0980","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12943-024-02145-1","article-title":"Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT\/BCL2\/BECN1 pathway","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0985","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2174\/1389201024666230821155243","article-title":"Anticancer Effect of Dihydroartemisinin via Dual Control of ROS-induced Apoptosis and Protective Autophagy in Prostate Cancer 22Rv1 Cells","volume":"25","author":"Yang","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bcp.2026.117802_b0990","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117802_b0995","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b1000","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b1005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.trecan.2017.04.002","article-title":"Targeting PI3K Signaling in Combination Cancer Therapy","volume":"3","author":"Pons-Tostivint","year":"2017","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b1010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metast. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b1015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.117802_b1020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mc.23458","article-title":"Therapeutic potential of the novel Bcl-2\/Bcl-X(L) dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer","volume":"61","author":"Qian","year":"2022","journal-title":"Mol. Carcinog."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b1025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1541-7786.MCR-20-0973","article-title":"Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells","volume":"19","author":"Kam","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117802_b1030","doi-asserted-by":"crossref","unstructured":"Q. Liu, J. Huang, W. Yan, Z. Liu, S. Liu, W. Fang, FGFR families: biological functions and therapeutic interventions in tumors, MedComm (2020) 4(5) (2023) e367.","DOI":"10.1002\/mco2.367"},{"issue":"32","key":"10.1016\/j.bcp.2026.117802_b1035","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","article-title":"Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition","volume":"37","author":"Weeden","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b1040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b1045","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-021-01470-4","article-title":"Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models","volume":"36","author":"Bertram","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bcp.2026.117802_b1050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-023-01898-w","article-title":"Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation","volume":"37","author":"Kielbassa","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b1055","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s12672-025-02947-9","article-title":"Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia","volume":"16","author":"Hays","year":"2025","journal-title":"Discov. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b1060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117802_b1065","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/ijms26073193","article-title":"Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice","volume":"26","author":"Zygmunciak","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b1070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.20892\/j.issn.2095-3941.2019.0380","article-title":"DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors","volume":"17","author":"Li","year":"2020","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117802_b1075","doi-asserted-by":"crossref","first-page":"9636","DOI":"10.1038\/s41598-024-59606-2","article-title":"Synthesis, bioactivity assessment, molecular docking and ADMET studies of new chromone congeners exhibiting potent anticancer activity","volume":"14","author":"Abo-Salem","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.117802_b1080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bcp.2026.117802_b1085","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1158\/1078-0432.CCR-19-1872","article-title":"Dual Targeting of CDK4\/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer","volume":"26","author":"Whittle","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b1090","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2022.281443","article-title":"Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia","volume":"108","author":"Pariury","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bcp.2026.117802_b1095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2026.117802_b1100","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7074","key":"10.1016\/j.bcp.2026.117802_b1105","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.bcp.2026.117802_b1110","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"9","key":"10.1016\/j.bcp.2026.117802_b1115","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117802_b1120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-18-0413","article-title":"Combined MEK and BCL-2\/X(L) Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness","volume":"18","author":"Iavarone","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b1125","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.3390\/ijms24054961","article-title":"Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins","volume":"24","author":"Peng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.117802_b1130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41419-019-1568-3","article-title":"BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival","volume":"10","author":"Lee","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.117802_b1135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2020.11.036","article-title":"BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells","volume":"499","author":"Hartman","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.117802_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2025.100230","article-title":"Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids","volume":"33","author":"Coussens","year":"2025","journal-title":"SLAS Discov."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:10:29Z","timestamp":1779109829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226001334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":228,"alternative-id":["S0006295226001334"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117802","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-targeting Bcl-2-mediated apoptosis and synergistic pathways: Combinatorial strategies to overcome therapeutic resistance in cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117802"}}